Malastad (Proguanil Hydrochloride, Atovaquone)

Atovaquone interferes with the parasite's mitochondrial electron transport chain, halting energy production, while proguanil is metabolised to cycloguanil, which blocks the parasite's dihydrofolate reductase enzyme. Together they provide a synergistic effect that stops parasite replication.

The dosage of Malastad is determined by the prescribing clinician based on the patient’s age, weight, indication (prophylaxis or treatment), and local resistance patterns. Patients should follow the prescriber’s instructions exactly.

Safety of Malastad in pregnancy and lactation has not been established. Healthcare providers must weigh the potential benefits against possible risks and consider alternative therapies when appropriate.

To order Malastad, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Malastad combines two agents with complementary mechanisms, offering broader activity and reduced resistance risk compared with single‑component drugs such as chloroquine or mefloquine. Its efficacy is comparable to other combination therapies like artemisinin‑based regimens, but choice depends on regional resistance patterns and patient factors.

Malastad should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged.

Malastad is taken orally, usually with food or a milky drink to enhance absorption of atovaquone. The exact timing and frequency are prescribed by the healthcare professional and should be adhered to for optimal effectiveness.

Serious risks include severe hypersensitivity reactions such as rash, itching, or anaphylaxis, hepatotoxicity manifested by elevated liver enzymes or jaundice, and rare blood disorders like neutropenia. Patients should seek immediate medical attention if these symptoms occur.

Malastad is contraindicated in individuals with known hypersensitivity to proguanil, atovaquone, or any component of the formulation. It should also be avoided in patients with severe renal or hepatic impairment unless specifically advised by a physician.